Just a snippet to inform you of major corporate changes in the world of pharma.
The impact on us is not at all clear. Might be next to nothing.
GSK plans break-up after £10bn Pfizer deal
US firm to buy into consumer healthcare portfolio and pave way for long-term spin-off of drugs business
GlaxoSmithKline, one of the world’s biggest drugs groups, is to be broken up after the company agreed to spin off its consumer healthcare business in a £10bn joint venture with US rival Pfizer.
GSK, whose consumer brands include Sensodyne and Panadol, will have a controlling stake in the partnership of 68%, with Pfizer owning the remainder.
The FTSE 100 drugmaker said that within three years of closing the deal, it will demerge and float the consumer health business, splitting GSK into two distinct businesses: one focused on consumer, the other on pharmaceuticals and vaccines.